Outset Medical Inc (OM)

NASD · Healthcare · Medical Devices · USA

Outset Medical Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Outset Medical develops the Tablo Hemodialysis System, an FDA-cleared dialysis solution for hospitals, clinics, and home settings. The compact console integrates water purification and dialysate production with cloud connectivity, enabling remote monitoring and analytics for healthcare providers treating acute kidney injury and chronic kidney disease patients.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Outset Medical Inc stock.

Our verdict on OM

Overvalued: intrinsic value $1.88 per share, market price $3.16, margin of safety -68.4% (as of 2026-11-17).

A 0.8x revenue multiple, discounted for its losses, values the shares at $1.88; the price of $3.16 is 68% above that value.

ETFs with the most weight in OM

7 more funds hold it; the full list is part of the paid plan.

More on OM

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than OM in Medical Devices

34 more in this industry show a wider margin of safety.

Is OM undervalued or overvalued?

OM is overvalued (as of the 2026-11-17 close). A 0.8x revenue multiple, discounted for its losses, values the shares at $1.88; the price of $3.16 is 68% above that value.

What is the intrinsic value of OM?

$1.88 per share (as of the 2026-11-17 close), against a market price of $3.16. That is a margin of safety of -68.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.